Builder.ai Strengthens Leadership with Craig Saunders from Amazon as New Vice President of Artificial Intelligence
11.6.2024 14:00:00 EEST | Business Wire | Press release
Builder.ai, the AI-powered composable software platform that allows every business and entrepreneur to become digitally powered, is excited to announce the appointment of Craig Saunders as Vice President of Artificial Intelligence. Craig Saunders, a powerhouse in the AI industry, joins Builder.ai from Amazon, where he spent seven transformative years within the Artificial General Intelligence (AGI) organisation.
During his tenure at Amazon, Craig made a significant impact by pioneering technologies for Alexa. He led research and engineering teams building foundational Knowledge Graphs for General Q&A on Alexa, established partnerships with leading universities, and his teams launched challenges within the academic community such as FEVER (Fact Extraction and Verification) to move the state of the art forward on factual accuracy of knowledge graphs. His leadership extended to Natural Language Understanding, including use of seq2seq models in Alexa, and formed the team that federated across multiple Alexa Q&A systems. In 2022, Craig led teams that were building the next generation of textual Large Language Models for Amazon, and advanced personalisation for Alexa.
“Craig’s remarkable achievements in AI - and his visionary approach to multi disciplinary, multi modal AI will enable us to propel Natasha and our AI capabilities to newer frontiers and allow us to drive an even richer customer experience,” said Sachin Dev Duggal, Founder & Chief Wizard, Builder.ai. “His expertise is not just in technology, but in fostering scaled innovation that resonates with customers on a global scale. I’m thrilled to have Craig join the team and excited to see what he and the team add to the Platform and Natasha’s capabilities.”
In his new role, Saunders will lead the AI teams at Builder.ai, focusing on scaling and expanding the company's existing AI capabilities, including Natasha, the world’s first AI product manager, and its new Code Generation System, which automates the transition from a user conversation directly to working code. His expertise will be instrumental in propelling Builder.ai to deliver even more for their customers through tailored software solutions with unprecedented efficiency.
“Joining Builder.ai feels like a natural progression in my career, allowing me to further push the boundaries of AI and machine learning solutions,” adds Craig Saunders. “I’m excited to be a part of the development of cutting-edge AI solutions that will not only transform the way software is created but also empower our customers to achieve their ambitious business goals.”
Craig received a PhD in Machine Learning from the University of London in 2000 and continued in the education sector, working nine years as an academic faculty at Royal Holloway, University of London and the University of Southampton. Utilising his expertise and knowledge, he transitioned to a career at Xerox where he delivered machine learning solutions across diverse industries including transportation, healthcare, and finance. Additionally, Craig has successfully published over 70 academic papers in leading conferences and journals, and holds several patents.
Established in 2016, Builder.ai leads the industry with its AI-powered composable software platform, allowing anyone with an idea to develop an app (web or mobile) more quickly and affordably. By decomposing software into reusable Lego-like features and combining them with cutting-edge AI and a patented software assembly line, Builder.ai has demonstrated global success in enabling customers of all sizes to adopt a software-first approach.
About Builder.ai
Builder.ai® is an AI-powered composable software platform for every idea and company globally. The AI-powered assembly line integrates Lego-like reusable features with Building Blocks™ automation to minimise human effort, leverages a verified network of experts to significantly extend development capabilities, and produces apps with a nearly zero failure rate at a fraction of the cost and time of traditional software development.
Led by serial entrepreneur Sachin Dev Duggal, Builder.ai is reshaping the construction and operation of software with a suite of products and services, including BUILDER STUDIO, BUILDER CLOUD, BUILDER NOW, and STUDIO STORE. Builder.ai was featured on the 2023 Fast Company list of Most Innovative Companies, received the “Hottest AI Startup” and 2022’s “Hottest Scale-Up” awards at the Europas for Europe's successful tech startups, and won the Best COVID-19 Innovation for Recovery at CogX. It was also named 'Visionary' in the 2021 Gartner® Magic Quadrant™ for Multi-experience Development Platforms. Builder.ai is headquartered in London, with employees and hubs in Delhi NCR, Singapore, Los Angeles, Salt Lake City, Sophia Antipolis, and Dubai. For more information, visit Builder.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611122778/en/
Contacts
Stephanie.lowenthal@builder.ai
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom